AAA August 2016 – Page 14

Big Deal: GSK seeks truth with Alphabet

Three years ago, in August 2013, Global Corporate Venturing’s Big Deal analysis said: “GSK electrifies with first deal” referring to UK-based drugs maker GlaxoSmithKline’s $50m bioelectronics fund, Action Potential Venture Capital (APVC). That deal was for SetPoint Medical, which subsequently raised a $43m series C round last year also including APVC. APVC’s other portfolio companies… Continue reading Big Deal: GSK seeks truth with Alphabet